Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive blood cancer, often involving the skin, bone marrow, lymph nodes, and central nervous system (CNS) in 20% to 30% of patients. Despite significant progress in CD123- and BCL-2–targeted therapy, most patients are not cured...

Descripción completa

Detalles Bibliográficos
Autores principales: Pemmaraju, Naveen, Wilson, Nathaniel R., Garcia-Manero, Guillermo, Sasaki, Koji, Khoury, Joseph D., Jain, Nitin, Borthakur, Gautam, Ravandi, Farhad, Daver, Naval, Kadia, Tapan, DiNardo, Courtney, Jabbour, Elias, Pierce, Sherry, Qazilbash, Muzaffar, Konopleva, Marina, Kantarjian, Hagop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131912/
https://www.ncbi.nlm.nih.gov/pubmed/35061885
http://dx.doi.org/10.1182/bloodadvances.2021006645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131912/
https://www.ncbi.nlm.nih.gov/pubmed/35061885
http://dx.doi.org/10.1182/bloodadvances.2021006645

Ejemplares similares